“Diagnosis, Prognosis, and Treatment of Immunoglobulin Light Chain Amyloidosis: Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone as First-Line Therapy and the Challenge of Delayed Diagnosis”

https://pubmed.ncbi.nlm.nih.gov/38095141

The abstract provides an update on the diagnosis, prognosis, and treatment of immunoglobulin light chain amyloidosis, a clonal plasma cell disorder, highlighting the use of daratumumab, bortezomib, cyclophosphamide, and dexamethasone as the current first-line therapy, and the future challenge of delayed diagnosis.